The possibility that BCL2 may not be as important in maintaining the cellular health of SS cells and that BCLxL may be more easily poisoned than BCL2 has been discussed, and the BCL2 family, rather than BCL2 alone, is considered a viable therapeutic target [38]. The gene discussed is BCL2; the disease is synovial sarcoma.